PIK3CA and neoplasm: Taselisib plus radiation therapy completely inhibited cancer cell growth, while no significant difference between gross tumor volume was observed at the beginning and end of therapy after three months.58,304 LY294002 and copanlisib (BAY 80-6946) were also developed in cancer cell xenograft models.305–307 Moreover, patients who responded to PI3K inhibitors acquired drug resistance over time.